Featured Story

Blocking cell-to-cell communication shows efficacy in mouse model of glioblastoma

An assistant professor of neurosurgery at The University of Florida (UF) College of Medicine has demonstrated a novel therapeutic strategy to significantly slow the growth of an aggressive brain tumour.

A small molecule 'exercise mimetic' may help control Type 2 diabetes and obesity

Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.

NIH successfully completes animal studies for new MERS vaccine

Zeroing in on the structure of a viral protein that Middle East respiratory syndrome (MERS) uses to enter and infect cells, a group of investigators at the NIH say they have developed a new vaccine that has proven promising in animal studies.

CSHL researchers report promising mouse study for Rett syndrome

Professor Nicholas Tonks and colleagues at Cold Spring Harbor Laboratory say that they've seen a promising response to PTP1B inhibitors in mouse models of Rett syndrome, an X-linked disorder that generally kills boys early in life while severely disrupting the lives of girls.

NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's

With the Alzheimer's Association International Conference underway in Washington, DC, there's been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.


From Our Sister Sites


Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during a Senate committee hearing on Thursday.


ResMed increased its focus on sleep disorder devices by acquiring China's Curative Medical for an undisclosed sum, in an attempt to gain a foothold in a fast-growing market.